- BrainsWay (BWAY, Financial) reported a record quarterly revenue of $11.5 million in Q1 2025, a 27% increase year-over-year.
- Operating profit surged by 519% to $0.6 million, and net profit saw an 897% increase to $1.1 million.
- Record shipment of 81 Deep TMS systems, marking a 42% increase compared to the previous year.
BrainsWay Ltd. (BWAY), a leader in noninvasive neurostimulation technologies, announced robust financial results for the first quarter of 2025. The company reported a record quarterly revenue of $11.5 million, representing a 27% year-over-year increase.
The operating profit for Q1 2025 significantly increased by 519% to reach $0.6 million, while the adjusted EBITDA rose by 81% to $1.3 million. Net profit surged by an impressive 897%, totaling $1.1 million, underlining strong financial performance and effective cost management.
The company achieved a record shipment of 81 Deep Transcranial Magnetic Stimulation (TMS) systems, reflecting a 42% increase from the previous year's first quarter, showcasing growing market adoption and demand for its technology.
BrainsWay maintained a steady gross margin of 75% and reported a strong cash position with $71.9 million in cash, cash equivalents, and short-term deposits as of March 31, 2025. This financial stability allows the company to continue investing in research and development.
The company has reaffirmed its full-year 2025 guidance, predicting revenue between $49 million and $51 million, with an operating profit margin of 3-4% and an adjusted EBITDA margin of 11-12%. Management has emphasized progress in clinical trials, particularly focusing on accelerated treatment protocols for major depressive disorder (MDD).
BrainsWay’s strategic focus includes expanding its reach within large enterprise customers, enhancing global sales channels, and leveraging clinical trials to bolster treatment options, which collectively position the company for sustained growth in the coming quarters.
